Ginkgo Bioworks (DNA) News Today → Log Into Marc's $5,000 System Today (From Chaikin Analytics) (Ad) Free DNA Stock Alerts $0.63 -0.03 (-4.46%) (As of 02:34 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 25 at 7:10 PM | finance.yahoo.com3 Things You Need to Know if You Buy Ginkgo Bioworks TodayMay 25 at 8:30 AM | fool.com3 Things You Need to Know if You Buy Ginkgo Bioworks TodayMay 25 at 4:57 AM | fool.comDown 72%. Is Ginkgo Bioworks a Buy on the Dip?May 23, 2024 | marketbeat.comGinkgo Bioworks (NYSE:DNA) Sees Strong Trading VolumeGinkgo Bioworks (NYSE:DNA) Sees Strong Trading VolumeMay 22, 2024 | marketbeat.comGinkgo Bioworks (NYSE:DNA) Hits New 52-Week Low at $0.69Ginkgo Bioworks (NYSE:DNA) Hits New 12-Month Low at $0.69May 22, 2024 | americanbankingnews.comGinkgo Bioworks (NYSE:DNA) Stock Price Down 4.3% After Insider SellingMay 21, 2024 | marketbeat.comGinkgo Bioworks (NYSE:DNA) Shares Down 4.3% on Insider SellingGinkgo Bioworks (NYSE:DNA) Stock Price Down 4.3% Following Insider SellingMay 21, 2024 | americanbankingnews.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Director Marijn E. Dekkers Sells 265,000 Shares of StockMay 21, 2024 | insidertrades.comMarijn E. Dekkers Sells 265,000 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) StockMay 20, 2024 | marketbeat.comGinkgo Bioworks (NYSE:DNA) Shares Gap Up to $0.81Ginkgo Bioworks (NYSE:DNA) Shares Gap Up to $0.81May 20, 2024 | fool.comGinkgo Bioworks Stock Has 37.5% Downside, According to 1 Wall Street AnalystMay 18, 2024 | fool.comIs Ginkgo Bioworks Holdings Stock a Buy?May 18, 2024 | americanbankingnews.comAnalysts Set Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) PT at $2.20May 16, 2024 | fool.com4 Small-Cap Value Stocks That Could Go ParabolicMay 16, 2024 | marketbeat.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Growth in Short InterestGinkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) saw a significant growth in short interest in April. As of April 30th, there was short interest totalling 289,730,000 shares, a growth of 8.7% from the April 15th total of 266,530,000 shares. Approximately 20.8% of the company's shares are short sold. Based on an average trading volume of 30,860,000 shares, the short-interest ratio is presently 9.4 days.May 15, 2024 | msn.comGinkgo slips as BTIG cuts to Sell on strategic shiftMay 15, 2024 | marketbeat.comGinkgo Bioworks (NYSE:DNA) Stock Price Down 7.9% Following Analyst DowngradeGinkgo Bioworks (NYSE:DNA) Shares Down 7.9% on Analyst DowngradeMay 15, 2024 | marketbeat.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Given Average Rating of "Reduce" by BrokeragesShares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) have earned a consensus recommendation of "Reduce" from the five analysts that are presently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a sell recommendation, one has assigned a holMay 15, 2024 | marketbeat.comGinkgo Bioworks (NYSE:DNA) Price Target Cut to $1.00 by Analysts at Morgan StanleyMorgan Stanley cut their price objective on Ginkgo Bioworks from $2.00 to $1.00 and set an "equal weight" rating on the stock in a research report on Wednesday.May 15, 2024 | marketbeat.comGinkgo Bioworks (NYSE:DNA) Lowered to Sell at BTIG ResearchBTIG Research lowered shares of Ginkgo Bioworks from a "neutral" rating to a "sell" rating in a research note on Wednesday.May 15, 2024 | insidertrades.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Director Harry Sloan Purchases 297,619 SharesMay 15, 2024 | prnewswire.comGinkgo Bioworks to Participate in Two Conferences in MayMay 14, 2024 | marketbeat.comInsider Buying: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Director Buys 297,619 Shares of StockGinkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) Director Harry Sloan purchased 297,619 shares of the firm's stock in a transaction on Tuesday, May 14th. The stock was acquired at an average cost of $0.91 per share, for a total transaction of $270,833.29. Following the completion of the purchase, the director now owns 718,540 shares in the company, valued at approximately $653,871.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.May 14, 2024 | marketbeat.comGinkgo Bioworks (NYSE:DNA) Trading 13.7% Higher Ginkgo Bioworks (NYSE:DNA) Trading 13.7% HigherMay 14, 2024 | prnewswire.comSojitz Corporation and Ginkgo Bioworks Announce Plans to Use Synthetic Biology R&D Services to Accelerate Sustainable Manufacturing in JapanMay 13, 2024 | finance.yahoo.comGinkgo Bioworks Receives Continued Listing Standard Notice From NYSEMay 13, 2024 | seekingalpha.comGinkgo Bioworks: Massive Revenue WarningMay 11, 2024 | finance.yahoo.comGinkgo Bioworks Holdings First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 10, 2024 | bizjournals.comGinkgo to reduce headcount, physical footprint after disappointing Q1May 10, 2024 | finance.yahoo.comGinkgo Bioworks Holdings Inc (DNA) Reports Q1 2024 Results: A Comprehensive OverviewMay 10, 2024 | msn.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Q1 2024 Earnings Call TranscriptMay 10, 2024 | marketbeat.comGinkgo Bioworks (NYSE:DNA) Posts Earnings Results, Hits EstimatesGinkgo Bioworks (NYSE:DNA - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.08). Ginkgo Bioworks had a negative net margin of 355.08% and a negative return on equity of 48.23%. The business had revenue of $37.94 million during the quarter, compared to analyst estimates of $45.50 million. During the same quarter in the previous year, the firm earned ($0.08) earnings per share.May 10, 2024 | msn.comGinkgo Bioworks slips on guidance cut; William Blair downgradesMay 10, 2024 | marketbeat.comGinkgo Bioworks (NYSE:DNA) Lowered to "Underperform" at William BlairWilliam Blair lowered Ginkgo Bioworks from a "market perform" rating to an "underperform" rating in a research note on Friday.May 9, 2024 | msn.comGinkgo Bioworks Stock Falls On Disappointing Q1 Sales: 'This Trend Needs To Change'May 9, 2024 | seekingalpha.comGinkgo Bioworks Holdings, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 9, 2024 | prnewswire.comGinkgo Bioworks Reports First Quarter 2024 Financial ResultsMay 7, 2024 | investorplace.comWant $10,000? Invest $1,000 in These 3 Penny Stocks NowMay 7, 2024 | prnewswire.comGreenLab Partners with Ginkgo Bioworks to Scale Up Production of Brazzein, a Novel SweetenerMay 7, 2024 | insidertrades.comMark E. Dmytruk Sells 47,806 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) StockMay 6, 2024 | marketbeat.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Insider Sells $40,157.04 in StockGinkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) insider Mark E. Dmytruk sold 47,806 shares of the firm's stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $0.84, for a total transaction of $40,157.04. Following the completion of the sale, the insider now owns 925,400 shares of the company's stock, valued at approximately $777,336. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.May 6, 2024 | prnewswire.comGinkgo Bioworks Announces Presentations at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual MeetingMay 5, 2024 | finance.yahoo.comRecent uptick might appease Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) institutional owners after losing 25% over the past yearMay 4, 2024 | marketbeat.comVestmark Advisory Solutions Inc. Invests $5.04 Million in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)Vestmark Advisory Solutions Inc. purchased a new position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 2,984,617 shares of theMay 3, 2024 | marketbeat.comGinkgo Bioworks (NYSE:DNA) Trading 9.4% Higher Ginkgo Bioworks (NYSE:DNA) Trading 9.4% HigherMay 3, 2024 | marketbeat.comGinkgo Bioworks (DNA) Set to Announce Earnings on ThursdayGinkgo Bioworks (NYSE:DNA) will be releasing earnings after the market closes on Thursday, May 9, Zacks reports.May 2, 2024 | prnewswire.comGinkgo Bioworks Announces Date of First Quarter 2024 Results PresentationApril 30, 2024 | marketbeat.comGinkgo Bioworks (NYSE:DNA) Trading Down 7.8%Ginkgo Bioworks (NYSE:DNA) Trading Down 7.8%April 30, 2024 | fool.comGinkgo Bioworks: Buy, Sell, or Hold?April 29, 2024 | investorplace.comIs a Giant Short Squeeze in Ginkgo Bioworks (DNA) Stock? Get Ginkgo Bioworks News Delivered to You Automatically Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Log Into Marc's $5,000 System Today (Ad)New Panic Could Sweep America Mark these words in 2024. Everyone's going to cash… Wall Street legend says: "A little-known vehicle outside of banks could double… triple… or even quadruple your life savings if you know where to find it right now." We urge you to move your cash into this vehicle in 2024. More here. DNA Media Mentions By Week DNA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DNA News Sentiment▼0.160.92▲Average Medical News Sentiment DNA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DNA Articles This Week▼75▲DNA Articles Average Week Get Ginkgo Bioworks News Delivered to You Automatically Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Halozyme Therapeutics News Today CRISPR Therapeutics News Today Krystal Biotech News Today ImmunityBio News Today Immunovant News Today SpringWorks Therapeutics News Today Apogee Therapeutics News Today Iovance Biotherapeutics News Today Arcellx News Today Denali Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:DNA) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesThe only AI company to buyPorter & CompanyThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaDigitizing the $11T commodities sector with one tiny stockResource Stock DigestWARNING about the death of the U.S. dollar…Colonial MetalsBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsIs Artificial Intelligence the Biggest Bubble in History?InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ginkgo Bioworks Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
